OSA is categorized by severity, and mild sleep apnea can often be minimized through lifestyle changes. Quitting smoking and ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

The recent FDA approval of the GLP-1 therapy tirzepatide for OSA represents a significant milestone in the treatment landscape for this complex disease. GLP-1 therapies have demonstrated efficacy ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Adults with obstructive sleep apnea (OSA) are at increased risk for vertigo and vestibular dysfunction, relative to those without OSA.

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...